期刊文献+

2000—2015年欧盟孤儿药认定及上市情况分析 被引量:1

An analysis on designation and marketing authorizations of orphan medicinal products from 2000 to 2015 in EU
原文传递
导出
摘要 通过欧盟药品监督管理局、欧盟委员会网站查阅,收集2000—2015年欧盟孤儿药政策法规、孤儿药认定及上市许可信息。孤儿药法规实施16年来,欧盟认定了1 596个孤儿药(年均约100个),上市许可121个孤儿药(年均约8个)。本文在分析欧盟孤儿药政策法规的基础上,对2000—2015年欧盟孤儿药认定和上市许可情况进行分析,为我国孤儿药政策法规制定和孤儿药研发提供参考。 We read the regulations and policies on orphan medicinal products, and collected the information of designation and marketing authorization for orphan medicinal products on the EMA and European Commission websites. Since this regulation for orphan medicinal products has entered into force for 16 years, 1596 medicines (annual average of about 100) have been granted orphan status by the European Commission, and 121 orphan designated medicines (annual average of about 8) have been authorized for marketing in the European Union. On the basis of the analysis of European policies and regulations for orphan medicinal products, we statistically analyzed the designation and marketing authorization for orphan medicinal products between 2000 and 2015, for providing a reference to enaction of orphan medicinal products' policies and regulations, and its research and development in China.
作者 李轩 都晓春 宗欣 LI Xuan DU Xiao-chun ZONG Xin(School of Management, Changchun University of Chinese Medicine, Changchun 130117, China Information Center of China Food and Drug Administration, Beijing 100053, China)
出处 《中国新药杂志》 CAS CSCD 北大核心 2016年第24期2761-2765,共5页 Chinese Journal of New Drugs
关键词 欧盟 孤儿药法规 孤儿药委员会 孤儿药认定 上市许可 European Union regulation on orphan medicinal products Committee for Orphan Medicinal Products orphan medicinal products designation marketing authorization
  • 相关文献

参考文献1

二级参考文献12

  • 1Reuters T. Cortellis [EB/OL]. [2014-06-18]. http://ip- science.thomsonreuters.com/info/newport whitepapers/. 被引量:1
  • 2FDA. Search orphan drug designations and approvals [EB/ OL]. [2014-05-24]. http://www.accessdata.fda.gov/scripts/ opdlisting/oopd/index.cfm. 被引量:1
  • 3The economic power of orphan drugs [EB/OL].[2014-05-24]. http://Thomsonreuters.com/business-unit/ science/subsector/pdf/the-economic-power-of-orphan-drugs. pdf. 被引量:1
  • 4Evaluate Pharma. Orphan drug report 2013 [EB/OL]. [2014-05-24] . http://www.evaluatgroup.com/ orphandrug2013. 被引量:1
  • 5NIH. About ORDR EEB/OL]. [2014-05-24]. http:// rarediseases.info.nih.gov/about-ordr/pages/30/about-ordr. 被引量:1
  • 6许焱.我国罕见病药品可及性评价指标体系的构建与影响因素分析[D].武汉:华中科技大学硕士学位论文,2012. 被引量:1
  • 7Le Cam Y. Inventory of access and prices of orphan drugs across Europe: a collaborative work between national alliances on rare diseases & eurordis. [EB/OL]. [2014-05-24]. http:// img.eurordis.org/newsletter/pdf/mar-2011/ERTC 13122010_ YLeCam_Final.pdf. 被引量:1
  • 8Tambuyzer E. Rare diseases, orphan drugs and their regulation: questions and misconceptions [J]. Nat Rev Drug Discovery, 2010, 9 (12) : 921-929. 被引量:1
  • 9Schieppati A, Henter J, Daina E, et al. Why rare diseases are an important medical and social issue [J]. Lancet, 2008, 371 (9629): 2039-2041. 被引量:1
  • 10张玲,翟晓梅.罗尔斯正义论视角下的罕见病卫生政策问题[J].中国医学伦理学,2011,24(2):141-143. 被引量:9

共引文献10

同被引文献4

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部